BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

450 related articles for article (PubMed ID: 24513605)

  • 1. Effects of short-term metformin therapy associated with levothyroxine dose decrement on TSH and thyroid hormone levels in patients with thyroid cancer.
    Mousavi Z; Dourandish L; Rokni H; Sadeghi R; Rasoul Zakavi S
    Minerva Endocrinol; 2014 Mar; 39(1):59-65. PubMed ID: 24513605
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Quality of life in longterm exogenous subclinical hyperthyroidism and the effects of restoration of euthyroidism, a randomized controlled trial.
    Eustatia-Rutten CF; Corssmit EP; Pereira AM; Frölich M; Bax JJ; Romijn JA; Smit JW
    Clin Endocrinol (Oxf); 2006 Mar; 64(3):284-91. PubMed ID: 16487438
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Changes within the thyroid axis after long-term TSH-suppressive levothyroxine therapy.
    Verburg FA; Smit JW; Grelle I; Visser TJ; Peeters RP; Reiners C
    Clin Endocrinol (Oxf); 2012 Apr; 76(4):577-81. PubMed ID: 22017394
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Glucose tolerance and lipid profile in longterm exogenous subclinical hyperthyroidism and the effects of restoration of euthyroidism, a randomised controlled trial.
    Heemstra KA; Smit JW; Eustatia-Rutten CF; Heijboer AC; Frölich M; Romijn JA; Corssmit EP
    Clin Endocrinol (Oxf); 2006 Dec; 65(6):737-44. PubMed ID: 17121524
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Altered bioavailability due to changes in the formulation of a commercial preparation of levothyroxine in patients with differentiated thyroid carcinoma.
    Olveira G; Almaraz MC; Soriguer F; Garriga MJ; Gonzalez-Romero S; Tinahones F; Ruiz de Adana MS
    Clin Endocrinol (Oxf); 1997 Jun; 46(6):707-11. PubMed ID: 9274701
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Thyrotropin suppression and disease progression in patients with differentiated thyroid cancer: results from the National Thyroid Cancer Treatment Cooperative Registry.
    Cooper DS; Specker B; Ho M; Sperling M; Ladenson PW; Ross DS; Ain KB; Bigos ST; Brierley JD; Haugen BR; Klein I; Robbins J; Sherman SI; Taylor T; Maxon HR
    Thyroid; 1998 Sep; 8(9):737-44. PubMed ID: 9777742
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Administration of thyroxine in treated Graves' disease. Effects on the level of antibodies to thyroid-stimulating hormone receptors and on the risk of recurrence of hyperthyroidism.
    Hashizume K; Ichikawa K; Sakurai A; Suzuki S; Takeda T; Kobayashi M; Miyamoto T; Arai M; Nagasawa T
    N Engl J Med; 1991 Apr; 324(14):947-53. PubMed ID: 1900575
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Impact of Thyroid Hormone Therapy on Atherosclerosis in the Elderly With Subclinical Hypothyroidism: A Randomized Trial.
    Blum MR; Gencer B; Adam L; Feller M; Collet TH; da Costa BR; Moutzouri E; Dopheide J; Depairon M; Sykiotis GP; Kearney P; Gussekloo J; Westendorp R; Stott DJ; Bauer DC; Rodondi N
    J Clin Endocrinol Metab; 2018 Aug; 103(8):2988-2997. PubMed ID: 29846630
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Potential risks of the adverse effects of thyrotropin suppression in differentiated thyroid carcinoma].
    Reverter JL; Colomé E
    Endocrinol Nutr; 2011 Feb; 58(2):75-83. PubMed ID: 21247815
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Thyroidal effect of metformin treatment in patients with polycystic ovary syndrome.
    Rotondi M; Cappelli C; Magri F; Botta R; Dionisio R; Iacobello C; De Cata P; Nappi RE; Castellano M; Chiovato L
    Clin Endocrinol (Oxf); 2011 Sep; 75(3):378-81. PubMed ID: 21521311
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Serum osteoprotegerin and soluble receptor activator of nuclear factor kappaB ligand levels in patients with a history of differentiated thyroid carcinoma: a case-controlled cohort study.
    Giusti M; Cecoli F; Fazzuoli L; De Franchis V; Ceresola E; Ferone D; Mussap M; Minuto F
    Metabolism; 2007 May; 56(5):699-707. PubMed ID: 17445547
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Bone mineral density in women receiving thyroxine suppressive therapy for differentiated thyroid carcinoma.
    Chen CH; Chen JF; Yang BY; Liu RT; Tung SC; Chien WY; Lu YC; Kuo MC; Hsieh CJ; Wang PW
    J Formos Med Assoc; 2004 Jun; 103(6):442-7. PubMed ID: 15278189
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Highly sensitive determination of TSH in the follow-up of TSH-suppressive therapy of patients with differentiated thyroid cancer.
    Mann K; Saller B; Mehl U; Hörmann R; Moser E
    Nuklearmedizin; 1988 Feb; 27(1):24-8. PubMed ID: 3368333
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Hormonal therapy in differentiated carcinoma of the thyroid gland].
    Francia G; Davì MV; Petroziello A; Sussi PL
    Chir Ital; 1994; 46(4):56-8. PubMed ID: 7882445
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Degree of thyrotropin suppression in differentiated thyroid cancer without recurrence or metastases.
    Kamel N; Güllü S; Dağci Ilgin S; Corapçioğlu D; Tonyukuk Cesur V; Uysal AR; Başkal N; Erdoğan G
    Thyroid; 1999 Dec; 9(12):1245-8. PubMed ID: 10646665
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Delayed TSH recovery after dose adjustment during TSH-suppressive levothyroxine therapy of thyroid cancer.
    Kim HI; Kim TH; Kim H; Kim YN; Jang HW; Kim JH; Hur KY; Chung JH; Kim SW
    Clin Endocrinol (Oxf); 2017 Sep; 87(3):286-291. PubMed ID: 28375573
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effect of thyrotropin suppressive therapy on heart rate variability and QT dispersion in patients with differentiated thyroid cancer.
    Liu C; Lv H; Li Q; Fu S; Tan J; Wang C; Wang X; Ma Y
    Medicine (Baltimore); 2020 Jul; 99(28):e21190. PubMed ID: 32664162
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Benefits of thyrotropin suppression versus the risks of adverse effects in differentiated thyroid cancer.
    Biondi B; Cooper DS
    Thyroid; 2010 Feb; 20(2):135-46. PubMed ID: 20151821
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Low trabecular bone score in postmenopausal women with differentiated thyroid carcinoma after long-term TSH suppressive therapy.
    De Mingo Dominguez ML; Guadalix Iglesias S; Martin-Arriscado Arroba C; López Alvarez B; Martínez Diaz-Guerra G; Martinez-Pueyo JI; Ferrero Herrero E; Hawkins Carranza F
    Endocrine; 2018 Oct; 62(1):166-173. PubMed ID: 30014437
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [L-thyroxine therapy in differentiated thyroid carcinoma: criteria for evaluation of TSH suppression].
    Kowalczyk P; Roskosz J; Jurecka-Tuleja B; Gubała E; Czernik E; Jarzab B
    Wiad Lek; 2001; 54(5-6):268-76. PubMed ID: 11556209
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 23.